Como la semaglutida es un agonista del receptor de GLP-1, acta como si fuera un GLP-1 sinttico, teniendo las mismas acciones que el GLP-1 producido de forma natural en el intestino
Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Most Doubt the Trump Administration Will Lower Drug Costs for People Like Them, Though Three-Fourths of Republicans Expect It Will About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds
Please carefully refer to user's manual for other safety instructions
Because this medication significantly changes how your digestive system functions, your body needs time to adjust
But as it stands, GLP-1 medications for weight loss currently go for $12,000 to $18,000 per patient per year